All In Biotech

BLA 022210 · Eurand Pharma LTD

Zenpep

Pancrelipase (Amylase, Lipase, Protease) · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Aug 27, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

n/a

n/a Phase 3, n/a recruiting

FAERS reports

6,026

3,528 serious, 408 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 14, 2025.

ZENPEP ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. ZENPEP ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. ( 1 )

Mechanism: Pancreatic enzyme products contain a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglycerides, glycerol, and free fatty acids, protein into peptides and amino acids, and starch into dextrins and short chain sugars such as maltose and maltriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

8 products under this application
  • ZENPEP · PANCRELIPASE (AMYLASE 168,000USP UNITS; LIPASE 40,000USP UNITS; PROTEASE) 126,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • ZENPEP · PANCRELIPASE (AMYLASE 14,000USP UNITS; LIPASE 3,000USP UNITS; PROTEASE) 10,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • ZENPEP · PANCRELIPASE (AMYLASE 63,000USP UNITS; LIPASE 15,000USP UNITS; PROTEASE) 47,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • ZENPEP · PANCRELIPASE (AMYLASE 24,000USP UNITS; LIPASE 5,000USP UNITS; PROTEASE) 17,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • ZENPEP · PANCRELIPASE (AMYLASE 252,600USP UNITS; LIPASE 60,000USP UNITS; PROTEASE) 189,600USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • ZENPEP · PANCRELIPASE (AMYLASE 105,000USP UNITS; LIPASE 25,000USP UNITS; PROTEASE) 79,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • ZENPEP · PANCRELIPASE (AMYLASE 84,000USP UNITS; LIPASE 20,000USP UNITS; PROTEASE) 63,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription
  • ZENPEP · PANCRELIPASE (AMYLASE 42,000USP UNITS; LIPASE 10,000USP UNITS; PROTEASE) 32,000USP UNITS · CAPSULE, DELAYED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pancrelipase (Amylase" as an intervention, any sponsor and status, largest first.

All n/a trials
ClinicalTrials.gov returned an error (400). The numbers below may be missing or incomplete.

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea500
  • infective pulmonary exacerbation of cystic fibrosis451
  • hospitalisation329
  • death296
  • cystic fibrosis287
  • nausea279
  • headache255
  • fatigue238
  • pneumonia233
  • weight decreased222
  • drug ineffective209
  • abdominal pain205

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201010
201110
201225
201359
2014100
2015217
2016333
2017337
2018541
2019944
2020778
2021318
2022370
2023562
2024544
2025518
2026360

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zenpep (Lipase/Protease/Amylase)

2024 spending

$597M

Beneficiaries

58,375

259,162 claims

Per beneficiary

$10,234

$11.15 per unit

View as table
YearSpending
2020$0
2021$143,420,728
2022$328,785,216
2023$442,806,702
2024$597,436,409

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5 on PubMed

Sponsor: Eurand Pharma LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.